Liver disease progression and virological response: Entecavir rescue still possible in the setting of rtM204I lamivudineresistant mutation

Gut

Volumn 62, Issue 5, 2013, Pages 801-802

  Tan, Poh Seng ^a,b   Aung, Myat Oo ^a   Dan, Yock Young ^a,b   Lee, Yin Mei ^a,b   Lim, Kieron ^a,b   Low, How Cheng ^a,b   Lee, Guan Huei ^a,b   Thwin, Maung Aye ^a,b   Soon, Charlene ^a   Lim, Seng Gee ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; VIRAL PHENOMENA AND FUNCTIONS; VIROLOGICAL RESPONSE; VIRUS MUTATION;

ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; VIRUS REPLICATION;

EID: 84875858025     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303647     Document Type: Article

References (8)

1. Zoutendijk R, Reijnders JGP, Zoulim F, et al. for the VIRGIL Surveillance Study Group. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013;62:760-5.
2. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
3. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100.
4. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49: 1503-14.
5. Lee GH, Aung MO, Dan YY, et al. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance? J Med Virol Published Online First: 28 Sept 2012. doi: 10.1002/jmv.23392.
6. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 2009;25:387-94.
7. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689-96.
8. Leemans WF, Flink HJ, Janssen HL, et al. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 2006;44: 507-11. (Pubitemid 43227874)